ARAubin Ramon

Aubin Ramon

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Aubin Ramon has a total of 50 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Deep learning assessment of nativeness and pairing likelihood for antibody and nanobody design with AbNatiV2

    by Aubin Ramon, Niccolò Frassetto, Haowen Zhao, Xing Xu, Matthew Greenig, Shimobi Onuoha, Pietro Sormanni

    Most immune-system created antibodies balance good binding and stability with low toxicity and self-reactivity. Quantifying the nativeness of a candidate sequence - its likelihood of belonging to natural immune repertoires - has thus emerged as a valuable strategy for hit selection from synthetic libraries, optimization and humanization, and for guiding de novo design toward developable candidates. We previously introduced AbNatiV, a transformer-based VQ-VAE for nativeness assessment, which proved effective across multiple nanobody engineering tasks. However, AbNatiV1 operated on unpaired sequences, limiting applicability to conventional VH-VL antibodies. Moreover, its performance on nanobody nativeness was constrained by the limited number and diversity of nanobody repertoires available at the time. Here, we sequenced new camelid repertoires, curated additional recent datasets, and present AbNatiV2: an enhanced architecture comprising various models each trained on ≥20 million sequences. AbNatiV2 improves nanobody nativeness classification across held-out and diverse test sets, and more robustly detects nativeness changes upon CDR grafting. We also introduce p-AbNatiV2, a cross-attention model fine-tuned on 3.7 million paired human sequences. p-AbNatiV2 provides residue- and sequence-level humanness for VH/VL pairs and learns pairing-likelihood via noise-contrastive training. On held-out tests, it assigns the native pair a higher score in 74% of cases, substantially outperforming recent pairing models. Together, AbNatiV2 and p-AbNatiV2 extend nativeness assessment and engineering to both nanobodies and conventional antibodies, supporting design decisions at single-residue, Fv-sequence, and paired-domain levels. AbNatiV2 is available as downloadable software and webserver.


  • Open Access

    Engineering armoured in vivo CAR T cells through targeted delivery and transient mRNA gating

    by Kai Hu, Saket Srivastava, Biao Ma, Yajing Yang, Huimin Wang, Maurizio Mangolini, Jasvinder Hayre, Emily Souster, Rajesh Karattil, Aubin Ramon, et al.

    In vivo generation of chimeric antigen receptor (CAR) T cells offers an off-the-shelf, scalable alternative to ex-vivo therapies, but is constrained by inefficiency, toxicity and durability. We report the first armoured in-vivo CAR T platform with tunable, transient activity, that enhances safety and efficacy. Our platform utilises CD8 targeted lipid nanoparticles (LNP) to transiently deliver CAR and armouring membrane-bound IL12 mRNAs. Payloads utilize a T-cell-restricted (T-trex) strategy to constrain CAR and IL-12 expression to T cells, enabling potent antigen-dependent activity with spatio-temporal control. Selective targeting of T-cells with a T-trex CAR showed enhanced expression. The addition of T–trex IL12 mRNA provides a tunable, localised amplification of CAR function, enhancing antigen-dependent cytotoxicity and cytokine production with robust tumour control. These findings establish a novel dose-efficient armoured in-vivo CAR T approach and general framework for programmable immune cell engineering.

  • Open Access

    Disulphide and sequence-encoded conformational priors guide nanobody structure prediction

    by Montader Ali, Mateusz Jaskolowski, Matthew Greenig, Tung H. Nguyen, Mia Crnogaj, Eva Smorodina, Aubin Emmanuel Ramon, Haowen Zhao, Monica Lisa Fernandez-Quintero, Elodie Ghedin, et al.

    Nanobody binding is largely governed by the HCDR3 loop, which adopts distinct placement regimes relative to the framework: compact, framework-contacting (kinked blueprint) and solvent-exposed (extended blueprint). Many nanobodies also contain additional cysteines that form non-canonical disulphide bonds, imposing covalent constraints on binding-loop conformations. Current structure predictors are typically trained and benchmarked with smooth coordinate-based objectives, so models may appear reasonable under root-mean-square deviation (RMSD), while adopting an incorrect HCDR3 blueprint or failing to recover the native disulphide connectivity, impacting paratope geometry and functional interpretation. Here, we show that the HCDR3 blueprint is predictable from sequence alone, allowing for explicit constraints during modelling. We implement these principles into NbForge, a lightweight nanobody folding model that incorporates blueprint- and disulphide-aware inductive biases and is trained with filtered self-distillation. NbForge improves recovery of HCDR3 blueprint and non-canonical disulphide formation over previous lightweight models and achieves coordinate accuracy at par to state-of-the-art, large, resource-intensive predictors, while running at sub-second inference speed. We show that using NbForge monomer models as templates further improves the success rate of predicting nanobody-antigen complexes. Together, these results motivate blueprint- and disulphide-aware benchmarks for nanobody modelling beyond RMSD, and show that appropriate inductive biases can close the performance gap to heavyweight predictors. We make the sequence classifier (NbFrame) and NbForge available for download and via a user-friendly web server.


  • Open Access

    Deep learning assessment of nativeness and pairing likelihood for antibody and nanobody design with AbNatiV2

    by Aubin Ramon, Niccolò Frassetto, Haowen Zhao, Xing Xu, Matthew Greenig, Shimobi Onuoha, Pietro Sormanni

    1 Immune systems create antibodies that balance good binding and stability with low toxicity and self- reactivity. Quantifying the nativeness of a candidate sequence – its likelihood of belonging to natural immune repertoires – has thus emerged as a valuable strategy for hit selection from synthetic libraries, optimisation and humanisation, and for guiding de novo design towards developable candidates. We previously introduced AbNatiV, a transformer-based VQ-VAE for nativeness assessment, which proved effective across multiple nanobody engineering tasks. However, AbNatiV1 operated on unpaired sequences, limiting applicability to conventional VH-VL antibodies. Moreover, its performance on nanobody nativeness was constrained by the limited number and diversity of nanobody repertoires available at the time. Here, we sequenced new camelid repertoires, curated additional recent datasets, and present AbNatiV2: an enhanced architecture comprising various models each trained on ≥ 20 million sequences. AbNatiV2 improves nanobody nativeness classification across held-out and diverse test sets, and more robustly detects nativeness changes upon CDR grafting. We also introduce p-AbNatiV2, a cross-attention model fine-tuned on 3.7 million paired human sequences. p-AbNatiV2 provides residue- and sequence-level humanness for VH/VL pairs and learns pairing-likelihood via noise-contrastive training. On held-out tests, it assigns the native pair a higher score in 74% of cases, substantially outperforming recent pairing models. Together, AbNatiV2 and p-AbNatiV2 extend nativeness assessment and engineering to both nanobodies and conventional antibodies, supporting design decisions at single-residue, Fv-sequence, and paired-domain levels. We make AbNatiV2 available as downloadable software and webserver.


  • Open Access

    Development of potent humanized TNFα inhibitory nanobodies for therapeutic applications in TNFα-mediated diseases

    by Tao Yin, Aubin Ramon, Matthew Greenig, Pietro Sormanni, Luciano D’aDamio

    Tumor necrosis factor-alpha (TNFα) is a key pro-inflammatory cytokine implicated in the pathogenesis of numerous inflammatory and autoimmune diseases, including rheumatoid arthritis, inflammatory bowel disease, and neurodegenerative disorders such as Alzheimer's disease. Effective inhibition of TNFα is essential for mitigating disease progression and improving patient outcomes. In this study, we present the development and comprehensive characterization of potent humanized TNFα inhibitory nanobodies (TNFI-Nbs) derived from camelid single-domain antibodies. In silico analysis of the original camelid nanobodies revealed low immunogenicity, which was further reduced through machine learning-guided humanization and developability optimization. The two humanized TNFI-Nb variants we developed demonstrated high anti-TNFα activity, achieving IC₅₀ values in the picomolar range. Binding assays confirmed their high affinity for TNFα, underscoring robust neutralization capabilities. These TNFI-Nbs present valid alternatives to conventional monoclonal antibodies currently used in human therapy, offering potential advantages in potency, specificity, and reduced immunogenicity. Our findings establish a solid foundation for further preclinical development and clinical translation of TNFα-targeted nanobody therapies in TNFα-mediated diseases.


  • Open Access

    Highly potent novel multi-armoured IL13Ra2 CAR-T subverts the immunosuppressive microenvironment of Glioblastoma

    by Maurizio Mangolini, Saket Srivastava, Emily Souster, Yajing Yang, Huimin Wang, Rajesh Karattil, Liam Schultz, Biao Ma, Diana Pombal, Matthew Greenig, et al.

    SUMMARY: Glioblastoma remains one of the most challenging and lethal brain cancers, with limited treatment options. While CAR-T cells have shown promise in some patients, sustaining T-cell activity and overcoming the immunosuppressive tumour microenvironment remain significant hurdles. Here, we present an armoured CAR-T cell design to address these challenges and enhance persistence in GBM tumours. We developed a highly specific humanised single-domain antibody targeting IL13Rα2 and included it alongside four additional modular elements in a single retroviral vector for CAR-T generation. Our results demonstrate that this single-cassette CAR-T cell design possesses high resilience against TGF-β-mediated immunosuppression, enhanced tumour-killing capacity through IL-12 secretion while maintaining a favourable safety profile, extended persistence in the host, and an additional layer of safety control through the incorporation of a suicide switch. Importantly, despite its complexity, the construct can still be manufactured efficiently. These advancements represent a significant step forward in addressing key challenges associated with CAR-T cell therapy in solid tumours.


  • Open Access

    Prediction of protein biophysical traits from limited data: a case study on nanobody thermostability through NanoMelt

    by Aubin Ramon, Mingyang Ni, Olga Predeina, Rebecca Gaffey, Patrick Kunz, Shimobi Onuoha, Pietro Sormanni

    In-silico prediction of protein biophysical traits is often hindered by the limited availability of experimental data and their heterogeneity. Training on limited data can lead to overfitting and poor generalizability to sequences distant from those in the training set. Additionally, inadequate use of scarce and disparate data can introduce biases during evaluation, leading to unreliable model performances being reported. Here, we present a comprehensive study exploring various approaches for protein fitness prediction from limited data, leveraging pre-trained embeddings, repeated stratified nested cross-validation, and ensemble learning to ensure an unbiased assessment of the performances. We applied our framework to introduce NanoMelt, a predictor of nanobody thermostability trained with a dataset of 640 measurements of apparent melting temperature, obtained by integrating data from the literature with 129 new measurements from this study. We find that an ensemble model stacking multiple regression using diverse sequence embeddings achieves state-of-the-art accuracy in predicting nanobody thermostability. We further demonstrate NanoMelt's potential to streamline nanobody development by guiding the selection of highly stable nanobodies. We make the curated dataset of nanobody thermostability freely available and NanoMelt accessible as a downloadable software and webserver.


  • Open Access

    A direct computational assessment of vinculin-actin unbinding kinetics reveals catch bonding behavior

    by Willmor J. Peña Ccoa, Fatemah Mukadum, Aubin Ramon, Guillaume Stirnemann, Glen M. Hocky

    Vinculin forms a catch bond with the cytoskeletal polymer actin, displaying an increased bond lifetime upon force application. Notably, this behavior depends on the direction of the applied force, which has significant implications for cellular mechanotransduction. In this study, we present a comprehensive molecular dynamics simulation study, employing enhanced sampling techniques to investigate the thermodynamic, kinetic, and mechanistic aspects of this phenomenon at physiologically relevant forces. We dissect a catch bond mechanism in which force shifts vinculin between either a weakly- or strongly-bound state. Our results demonstrate that models for these states have unbinding times consistent with those from single-molecule studies, and suggest that both have some intrinsic catch bonding behavior. We provide atomistic insight into this behavior, and show how a directional pulling force can promote the strong or weak state. Crucially, our strategy can be extended to capture the difficult-to-capture effects of small mechanical forces on biomolecular systems in general, and those involved in mechanotransduction more specifically.


  • Open Access

    Assessing antibody and nanobody nativeness for hit selection and humanization with AbNatiV

    by Aubin Ramon, Montader Ali, Misha Atkinson, Alessio Saturnino, Kieran Didi, Cristina Visentin, Stefano Ricagno, Xing Xu, Matthew Greenig, Pietro Sormanni

    Monoclonal antibodies have emerged as key therapeutics. In particular, nanobodies, small, single-domain antibodies that are naturally expressed in camelids, are rapidly gaining momentum following the approval of the first nanobody drug in 2019. Nonetheless, the development of these biologics as therapeutics remains a challenge. Despite the availability of established in vitro directed-evolution technologies that are relatively fast and cheap to deploy, the gold standard for generating therapeutic antibodies remains discovery from animal immunization or patients. Immune-system-derived antibodies tend to have favourable properties in vivo, including long half-life, low reactivity with self-antigens and low toxicity. Here we present AbNatiV, a deep learning tool for assessing the nativeness of antibodies and nanobodies, that is, their likelihood of belonging to the distribution of immune-system-derived human antibodies or camelid nanobodies. AbNatiV is a multipurpose tool that accurately predicts the nativeness of Fv sequences from any source, including synthetic libraries and computational design. It provides an interpretable score that predicts the likelihood of immunogenicity, and a residue-level profile that can guide the engineering of antibodies and nanobodies indistinguishable from immune-system-derived ones. We further introduce an automated humanization pipeline, which we applied to two nanobodies. Laboratory experiments show that AbNatiV-humanized nanobodies retain binding and stability at par or better than their wild type, unlike nanobodies that are humanized using conventional structural and residue-frequency analysis. We make AbNatiV available as downloadable software and as a webserver.